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Metabolic consequences of obesity 
on the hypercoagulable state 
of polycystic ovary syndrome
Abu Saleh Md Moin1, Thozhukat Sathyapalan2, Ilhame Diboun3, Mohamed A. Elrayess4, 
Alexandra E. Butler1,6* & Stephen L. Atkin5,6
Polycystic ovary syndrome (PCOS) women have a hypercoagulable state; however, whether this is 
intrinsically due to PCOS or, alternatively, a consequence of its metabolic complications is unclear. 
We determined plasma coagulation pathway protein levels in PCOS (n = 146) and control (n = 97) 
women recruited to a PCOS biobank. Circulating levels of a panel of 18 clotting pathway proteins were 
determined by Slow Off-rate Modified Aptamer-scan plasma protein measurement. Cohorts were age 
matched, though PCOS had elevated body mass index (p < 0.001), insulin (p < 0.001) and C-reactive 
protein (CRP) (p < 0.0001). Eight pro-coagulation proteins were elevated in PCOS: plasminogen 
activator inhibitor-1 (p < 0.0001), fibrinogen (p < 0.01), fibrinogen gamma chain (p < 0.0001), fibronectin 
(p < 0.01), von Willebrand factor (p < 0.05), D-dimer (p < 0.0001), P-selectin (p < 0.05), and plasma 
kallikrein (p < 0.001). However, two anticoagulant proteins, vitamin K-dependent protein-S (p < 0.0001) 
and heparin cofactor-II (p < 0.001) were elevated and prothrombin was decreased (p < 0.05). CRP, as 
a marker of inflammation, and insulin resistance (HOMA-IR) correlated with 11 and 6 of the clotting 
proteins, respectively (p < 0.05). When matched for BMI < 25 (16 PCOS, 53 controls) HOMA-IR 
remained elevated (p < 0.05) and heparin cofactor-II was increased (p < 0.05). In a multivariate analysis 
accounting for inflammation, insulin resistance and BMI, there was no correlation of PCOS with any of 
the coagulation proteins. The hypercoagulable state in PCOS is not intrinsic to the disease as it can be 
fully accounted for by BMI, inflammation and insulin resistance.
PCOS has been recognized as a reproductive-metabolic disorder given the excess prevalence of type 2 diabetes, 
hypertension, and cardiovascular diseases in this population at a later stage in  life1. Polycystic ovary syndrome 
(PCOS) patients have increased platelet aggregation and decreased plasma fibrinolytic activity, resulting in a pro-
thrombotic  propensity2,3. Elevated coagulation markers have been reported in PCOS in comparison to  controls4 
and the coagulation parameters including prothrombin time, thrombin time and fibrin degradation products may 
be predictive of  PCOS5. It has been reported that coagulation proteins such as thrombin-activatable fibrinolysis 
inhibitor, PAI-1, D-dimer, Antithrombin III and thrombomodulin are significantly increased in women with 
PCOS compared with age- and BMI-matched  controls4. This suggests that PCOS, independent of its metabolic 
features, may be a risk factor for a hypercoagulable state.
This study was undertaken to determine the parameters contributing to the hypercoagulable state reported 
for PCOS.
Materials and methods
We determined plasma coagulation pathway protein levels in PCOS (n = 146) and control (n = 97) women 
recruited to a PCOS biobank (ISRCTN70196169). The Newcastle & North Tyneside Ethics committee approved 
this study which was conducted according to the Declaration of Helsinki. All patients gave written informed 
consent. Clinical data and samples were accessed from the PCOS Genetic Biobank in the UK, therefore the 
Newcastle & North Tyneside Ethics committee serves as a national center to provide ethical approval for these 
Biobank samples.
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All women were Caucasian. The diagnosis of PCOS was based on at least two out of three of the diagnostic 
criteria of the Rotterdam consensus as detailed  previously6; namely clinical and biochemical evidence of hyper-
androgenism (Ferriman-Gallwey score > 8; free androgen index > 4, total testosterone > 1.5 nmol/L), oligomenor-
rhea or amenorrhoea and polycystic ovaries on transvaginal ultrasound. Nonclassical 21-hydroxylase deficiency, 
hyperprolactinemia, Cushing’s disease and androgen secreting tumors were excluded by appropriate tests. The 
baseline study measurements have been described in detail  previously7 and the demographic data for the PCOS 
and control women is shown in Table 1. All the control women had regular periods, no clinical or biochemical 
hyperandrogenism, no polycystic ovaries on ultrasound, no significant background medical history and none of 
them were on any medications including oral contraceptive pills or over the counter medications.
Circulating levels of clotting pathway proteins were determined by Slow Off-rate Modified Aptamer (SOMA)-
scan plasma protein measurement, the details of which have been previously  reported8. Normalization of raw 
intensities, hybridization, median signal and calibration signal were performed based on the standard samples 
included on each plate, as previously  described9.
We used version 3.1 of the SOMAscan Assay, specifically targeting those proteins involved in the coagulation 
cascade and fibrinolysis pathway in the SOMAscan panel of 18 proteins, in line with a previous report for those 
involved in a hypercoagulable state and alteration in coagulation  proteins10: antithrombin III, heparin cofac-
tor 2, fibrinogen gamma chain, D-Dimer, P-selectin, fibronectin, fibronectin fragment 3, fibronectin fragment 
4, vitamin K dependent protein S, alpha 2 antiplasmin, fibrinogen, von Willebrand factor, plasma kallikrein, 
prothrombin, coagulation factor Xa, tissue factor, coagulation factor XI and angiostatin. Those proteins in the 
panel that inform us of a hypercoagulable state include fibrinogen and fibronectin as well as inhibition of the 
fibrinolytic pathway with plasminogen activator inhibitor-1 and evidence of activated fibrinolysis with D-Dimer 
 levels10–12 (Table 2).
Statistics. Measured protein data were log transformed to ascertain normality. Proteins were regressed on 
the continuous variables CRP, HOMA-IR and BMI in separate models to assess the extent of association with 
each trait. A multivariate linear model incorporating all three traits and PCOS status was performed to evalu-
ate the relationship between the measured proteins and PCOS whilst correcting for the traits. All analyses were 
performed using R version 4. P values were corrected for multiple testing using the false discovery rate (FDR).
Ethics approval. The Newcastle & North Tyneside Ethics committee approved this study which was con-
ducted according to the Declaration of Helsinki. All patients gave written informed consent. Clinical data and 
samples were accessed from the PCOS Genetic Biobank in the UK, therefore the Newcastle & North Tyneside 
Ethics committee serves as a national center to provide ethical approval for these Biobank samples.
Consent for publication. All authors gave their consent for publication.
Results
Cohorts were age matched, though PCOS had elevated BMI (p < 0.001), fasting glucose (p < 0.05), insulin 
(p < 0.001), C-reactive protein (p < 0.0001) and platelet number (p < 0.01).
Pro-coagulation proteins elevated in PCOS are shown in Fig. 1 and include plasminogen activator inhibitor-1 
(PAI-1) (2259 ± 137 vs 1457 ± 107 RFU, PCOS vs control, p < 0.0001), fibrinogen (177,423 ± 2108 vs 169,230 ± 2425 
RFU, PCOS vs control, p < 0.01), fibrinogen gamma chain (63,118 ± 946 vs 57,328 ± 830 RFU, p < 0.0001), fibronec-
tin (24,594 ± 2627 vs 16,041 ± 698 RFU, p < 0.01), von Willebrand factor (19,849 ± 3038 vs 13,159 ± 595 RFU, 
p < 0.05), D-dimer (13,860 ± 185 vs 12,708 ± 172 RFU, p < 0.0001), P-selectin (13,843 ± 317 vs 12,660 ± 412 RFU, 
p < 0.05), and plasma kallikrein (24,868 ± 376 vs 22,981 ± 447 RFU, p < 0.001). Prothrombin levels were decreased 
in PCOS (161,458 ± 1275 vs 165,233 ± 1958 RFU, p < 0.05) and the anticoagulant vitamin K-dependent protein S 
(4403 ± 69 vs 3989 ± 59 RFU, p < 0.0001) and heparin cofactor II (HCII) (4156 ± 64 vs 3821 ± 63 RFU, p < 0.001) 
were increased (Fig. 2). A schematic illustration of all the blood coagulation proteins altered in PCOS is shown 
in Fig. 3.
Table 1.  Demographics, baseline, hormonal and metabolic parameters of the PCOS subjects and controls. 
BMI Body mass index, HOMA-IR Homeostasis model of assessment-insulin resistance, CRP C reactive 
protein, SHBG Sex hormone binding globulin.
Baseline demographics
PCOS (n = 146) Controls (n = 97)
p valueMean (SD) Mean (SD)
Age (years) 29.1 (6.1) 29.6 (6.5) 0.09
BMI (Kg/m2) 34.1 (7.5) 26.7 (6.6)  < 0.0001
Weight (Kg) 96.5 (23.7) 74.4 (18.4)  < 0.0001
Insulin (IU/ml) 10.2 (6.1) 6.2 (3.2) 0.001
HOMA-IR 3.8 (0.6) 1.6 (0.2)  < 0.005
CRP (mg/L) 4.4 (4.2) 2.4 (3.9) 0.0008
SHBG (nmol/L) 42.5 (39.6) 77.5 (78.4) 0.0003
Testosterone (nmol/l) 1.6 (1.0) 1.05 (0.48)  < 0.0001
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Significant correlations of coagulation proteins with body mass index are shown in Table 2 and include 
antithrombin III (p < 0.0001), fibrinogen gamma chain (p < 0.0001), vitamin K dependent protein S (p < 0.001), 
D-dimer (p < 0.001), fibronectin (p < 0.001), prothrombin (p < 0.01), heparin cofactor 2 (p < 0.01), fibrinogen 
(p < 0.05), angiostatin (p < 0.05), fibrinogen fragment 3 (p < 0.05) and P-selectin (p < 0.05). Significant correlations 
of coagulation proteins with CRP, as a marker of inflammation, are shown in Table 2, that included antithrom-
bin III (p < 0.0001), heparin cofactor 2 (p < 0.0001), fibrinogen gamma chain (p < 0.0001), D-dimer (p < 0.0001), 
P-selectin (p < 0.001), fibronectin (p < 0.001), and its fragments 3 and 4 (p < 0.01, respectively), vitamin K depend-
ent protein S, alpha 2 antiplasmin and fibrinogen (p < 0.05, respectively). Significant correlations of coagulation 
proteins with insulin resistance, as determined by HOMA-IR, were also seen for antithrombin III (p < 0.0001), 
heparin cofactor 2 (p < 0.001), P-selectin (p < 0.0001), fibronectin (p < 0.01), vitamin K dependent protein S and 
alpha 2 antiplasmin (p < 0.05, respectively) (Table 2). However, in a multivariate analysis accounting for BMI, 
inflammation (CRP) and insulin resistance (HOMA-IR), there was no correlation with the coagulation proteins 
(Table 2).
To eliminate the confounding effect of obesity, a subset of women with BMI ≤ 25 kg/m2 (16 PCOS and 53 
controls) were compared. Here, HOMA-IR remained elevated in PCOS (1.6 ± 1.2 vs 1.1 ± 0.5, p < 0.05), CRP did 
not differ, whilst heparin cofactor 2 (3979 ± 649 vs 3613 ± 585 RFU, p < 0.05) was elevated in the normal weight 
PCOS group (Table 3).
Discussion
These data show that the hypercoagulable state in PCOS can be completely accounted for by BMI and its asso-
ciated inflammation, and enhanced insulin resistance. In comparison to the normal controls, overall 10 pro-
coagulation proteins were elevated in PCOS; plasminogen activator inhibitor-1 (PAI-1), fibrinogen, fibrinogen 
gamma chain, fibronectin, von Willebrand factor, D-dimer, P-selectin, plasma kallikrein. anticoagulant vitamin 
K-dependent protein S and heparin cofactor II, whilst prothrombin was decreased. These results are in accord 
with others who have reported changes in coagulation proteins in  PCOS4,13, but underlying pathophysiology has 
not been previously described and shows that in PCOS alterations in the coagulation factors appears complex 
and multifactorial. When normal weight (BMI ≤ 25) PCOS patients were compared with normal weight control 
subjects, insulin resistance remained elevated and heparin cofactor 2, that is protective and inactivates thrombin 
in tissues, differed. These data are in accord with the association of heparin cofactor 2 with insulin  resistance14, 
Table 2.  Correlation of coagulation proteins with (A) Body mass index (BMI), (B) inflammation (C reactive 
protein; CRP) and (C) insulin resistance (HOMA-IR), (D) shows the results of the multivariate analysis taking 
into account BMI, CRP and HOMA-IR. Bolded numbers indicate significant differences between PCOS and 
control groups, at the p < 0.05 level.
A. BMI B. CRP C. HOMA-IR D. CRP + BMI + HOMA-IR
p value r2 p value r2 p value r2 p value r2
Antithrombin.III  < 0.00001 0.154 Antithrombin III  < 0.00001 0.202 Antithrombin III  < 0.00001 0.140 D.dimer 0.06 0.151
Fibrinogen gamma 




protein S 0.0007 0.070
Fibrinogen gamma 
chain 0.00003 0.111 P.selectin 0.001 0.066 Fibrinogen 0.07 0.089
D.dimer 0.0008 0.068 D.dimer 0.00012 0.094 Fibronectin 0.009 0.042 Plasma kallikrein 0.09 0.051
Fibronectin 0.0008 0.068 P.selectin 0.0012 0.067 Vitamin.K dependent protein.S 0.015 0.037
Fibronectin Frag-
ment.4 0.12 0.064
Prothrombin 0.007 0.044 Fibronectin 0.0014 0.066 Alpha.2 antiplasmin 0.02 0.032 Vitamin.K dependent protein.S 0.14 0.089
Heparin cofactor.2 0.009 0.042 Fibronectin Frag-ment.3 0.006 0.050 Prothrombin 0.05 0.024 von Willebrand factor 0.14 0.035
Fibrinogen 0.013 0.038 Fibronectin Frag-ment.4 0.007 0.047
Fibronectin Frag-
ment.3 0.09 0.018 Coagulation factor.Xa 0.19 0.030
Angiostatin 0.014 0.037 Vitamin K dependent protein.S 0.02 0.037 Plasma kallikrein 0.18 0.011 Antithrombin.III 0.19 0.264
Fibronectin Frag-
ment.3 0.03 0.031 Alpha.2 antiplasmin 0.02 0.036 Tissue Factor 0.20 0.010 Fibronectin 0.24 0.094
P.selectin 0.04 0.026 Fibrinogen 0.02 0.035 Fibrinogen gamma chain 0.24 0.009
Fibronectin Frag-
ment.3 0.31 0.060
Alpha.2 antiplasmin 0.16 0.012 von Willebrand factor 0.12 0.016 Fibronectin Frag-ment.4 0.32 0.006 Tissue Factor 0.40 0.030
Fibronectin Frag-
ment.4 0.18 0.011 Plasma kallikrein 0.18 0.012 D.dimer 0.43 0.004 Angiostatin 0.41 0.056
Tissue.Factor 0.19 0.011 Prothrombin 0.19 0.011 Angiostatin 0.50 0.003 Prothrombin 0.42 0.048
von.Willebrand factor 0.26 0.008 Coagulation factor.Xa 0.22 0.010 Coagulation Factor.XI 0.81 0.000 Alpha.2 antiplasmin 0.42 0.052
Coagulation factor Xa 0.49 0.003 Tissue.Factor 0.71 0.001 Coagulation factor.Xa 0.83 0.000 Heparin cofactor 2 0.58 0.133
Coagulation Factor.XI 0.66 0.001 Coagulation Factor.XI 0.73 0.001 von Willebrand factor 0.87 0.000 Coagulation Factor.XI 0.70 0.005
Plasma kallikrein 0.97 0.000 Angiostatin 0.74 0.001 Fibrinogen 0.93 0.000 P.selectin 0.71 0.096
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Figure 1.  Pro-coagulation clotting pathway proteins that were increased in women with polycystic ovary 
syndrome (PCOS). Levels of plasma plasminogen activator inhibitor 1 (A), fibrinogen (B), fibrinogen gamma 
chain (C), fibronectin (D), von Willebrand factor (E), D-dimer (F), P-selectin (G) and plasma kallikrein (H) in 
women with and without polycystic ovary syndrome (PCOS). RFU, relative fluorescent units. Graphs shown as 
mean ± SEM. ^p < 0.05, *p < 0.01, **p < 0.001, ***p < 0.0001.
Figure 2.  Anti-coagulation clotting pathway proteins that were altered in women with polycystic ovary 
syndrome (PCOS). Levels of plasma prothrombin (A), Vitamin K dependent Protein S (B) and heparin cofactor 
II in women with and without polycystic ovary syndrome (PCOS). RFU, relative fluorescent units. Graphs 
shown as mean ± SEM. ^p < 0.05, **p < 0.001, ***p < 0.0001.
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Figure 3.  Schematic illustration showing altered coagulation pathway proteins in polycystic ovary syndrome 
(PCOS). Cellular stimulation factors and proteins involved in blood coagulation pathways [intrinsic (top left), 
extrinsic (top right) and fibrinolytic system (bottom left)] are illustrated. Proteins increased in women with 
PCOS are indicated by upward red arrows (labelled ‘PCOS’) with the protein decreased in PCOS (prothrombin) 
indicated by a downward red arrow. Red dotted lines indicate the inhibitory actions of the proteins in blood 
coagulation pathways.
Table 3.  Demographics, baseline, hormonal and metabolic parameters of the normal weight (BMI ≤ 25 kg/m2) 
PCOS subjects and controls (16 PCOS and 53 control women). BMI Body mass index, HOMA-IR Homeostasis 
model of assessment-insulin resistance, CRP C reactive protein, SHBG Sex hormone binding globulin.
Baseline demographics
PCOS (n = 16) Controls (n = 53)
p valueMean (SEM) Mean (SEM)
Age (years) 27.8 (1.7) 29.5 (0.9) 0.37
BMI (Kg/m2) 22.7 (0.5) 22.8 (0.3) 0.87
Weight (Kg) 64.1 (1.9) 63.0 (1.0) 0.59
Insulin (IU/ml) 8.9 (2.4) 5.0 (0.5) 0.02
HOMA-IR 1.6 (0.3) 1.1 (0.09) 0.04
CRP (mg/L) 1.2 (0.2) 0.9 (0.1) 0.22
SHBG (nmol/L) 72.7 (15.6) 95.9 (12.2) 0.33
Testosterone (nmol/l) 1.2 (0.1) 1.1 (0.1) 0.29
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indicating that normal weight PCOS subjects likely have no additional risk associated with a hypercoagulable 
state; however, obesity with associated inflammation markedly exaggerates the hypercoagulable state with an 
increased number of clotting parameters altered. The multivariate analysis showed that all of the changes in the 
coagulation proteins could be accounted for by BMI, inflammation and insulin resistance.
It is well recognized that obesity causes inflammation and increased insulin  resistance15,16 and is associated 
with changes in coagulation parameters. For example, fibronectin is correlated to  BMI17 and obesity is associated 
with increased PAI-1 in  PCOS18. Others have reported, using a repeated fibrin formation and degradation func-
tional assay, that “overall hemostatic potential” was BMI-dependent and not associated with  PCOS19. Central fat 
mass has been associated with fibrinogen, CRP, coagulation factor XIII, waist-to-hip ratio, plasminogen, PAI-1, 
plasmin inhibitor, and thrombin activatable fibrinolysis  inhibitor20).
Conversely, thrombin-activatable fibrinolysis inhibitor, PAI-1, D-dimer, Antithrombin III and thrombo-
modulin were reported to be significantly increased in women with PCOS compared with age- and BMI-matched 
controls, suggesting that alterations in these proteins are BMI-independent and due to other factors such as 
inflammation and insulin resistance, as reported  here4.
Inflammation (CRP) correlated significantly with antithrombin III, heparin cofactor 2, fibrinogen gamma 
chain, D-dimer, P-selectin, fibronectin, and its fragments 3 and 4, vitamin K dependent protein S, alpha 2 
antiplasmin and fibrinogen. Inflammation crosstalk with coagulation leading to increased coagulopathy is well 
recognized; however, with the initiation of coagulation, the coagulation proteases may then modulate the inflam-
matory  response21,22. In PCOS, both CRP and fibrinogen are predicted by BMI in accord with obesity initiating 
the increased  inflammation23 and particularly CRP, PAI-1, D-dimer, Antithrombin III with central fat mass as 
noted  above20.
In this study, insulin resistance (HOMA-IR) correlated with Antithrombin III, heparin cofactor 2, P-selectin, 
fibronectin, vitamin K dependent protein S and alpha 2 antiplasmin. It is recognized that insulin resistance is 
associated with enhanced  thrombogenesis24; however, it is difficult to determine the contribution of insulin 
resistance alone to its association with obesity and inflammation metabolic syndrome lipid  parameters25–27.
As noted above, there are reports of changes in coagulation proteins in  PCOS4,13 and changes in functional 
 assays2,3; however, conversely others have not found changes in the coagulation proteins between PCOS and 
 controls28. It can be seen from the data presented here that the likely reason for these discrepancies are due to the 
patient population being studied with the results dependent on the degree of obesity, inflammation and insulin 
resistance present. In addition, the PCOS phenotype may have an important role, with those having all three of 
the diagnostic criteria exhibiting the metabolic phenotype with increased insulin resistance in comparison to 
those with only two of the three diagnostic  criteria29.
The hypercoagulation state is in homeostasis with the pro-coagulation protein changes seen here in PCOS 
being balanced by the reduction in prothrombin and increased vitamin K-dependent protein S and heparin 
cofactor II that we also report.
Limitations of this study include that it was a cross sectional study, but this was mitigated by the large number 
of subjects. As all study subjects were Caucasian, these results may not be generalizable to other ethnic popula-
tions. Only BMI, rather than an assessment of visceral fat, was available for this study population. In addition, 
only the proteins involved in the coagulation cascade and fibrinolysis pathway were measured. It would have 
been optimal to have included prothrombin fragments 1 and 2 as markers of activated coagulation, but these 
were not available in the SOMAscan proteomics panel. Likewise, the thrombin generation assay would have 
been a good indicator of an increase in activated coagulation; however, no functional assays were undertaken 
in this study. Whilst there was no single good marker for activated coagulation it has well been recognised that 
indicators found here, such as high plasma fibrinogen, factor VII/VIIa, tissue-type plasminogen activator and 
plasminogen activator inhibitor levels, have been associated with at least as great a risk of developing myocardial 
(re)infarction or sudden death as high cholesterol levels, especially in the  young11.
In conclusion, the hypercoagulable state in PCOS can be fully accounted for by BMI, inflammation and insu-
lin resistance. This is an important finding because, whilst the prothrombotic propensity of women with PCOS 
has previously been reported, it was assumed to be intrinsic to the PCOS condition. Here, we show that this is, 
in fact, not the case, but is a consequence of the increased BMI, inflammation and insulin resistance that often 
accompany the PCOS condition; the impact of directed therapy needs to be determined in the future. Further 
studies in lean PCOS women would help to clarify our findings.
Data availability
All the data for this study will be made available upon reasonable request to the corresponding author.
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